October - 2000

Company

Company

Type/Product Area

Terms/Details

Aeson Therapeutics Inc.

Hollis-Eden Pharmaceuticals Inc. (HEPH)

Licensing agreement/Hollis-Eden obtained an exclusive worldwide sublicense to three issued patents in the area of adrenal steroids

In addition, Hollis-Eden is exchanging $2M in cash and 208,681 shares of its common stock for a 21% equity stake in Aeson, with an exclusive option to acquire the remainder at any time during the next 30 months

Allied Clinical Research Inc.

SignalGene Inc. (Canada; TSE:SGI)

Service agreement/SignalGene will apply its pharmacogenomics platform for the genotyping of drug- metabolizing enzymes on samples collected by Allied Clinical Research

ND

AngioSense Inc.

Repair Inc.

Development agreement/AngioSense will supply its needle-free, jet injection delivery systems and Repair will provide fibroblast growth factor (FGF) and fibrinogen constructs to jointly pursue clinical applications for sustained FGF delivery

Financial details were not disclosed

ArQule Inc. (ARQL)

Genome Therapeutics Corp. (GENE)

Discovery collaboration/ArQule will use its new Parallel Track Drug Discovery program to screen and optimize compounds against an expanded number of validated anti-infective targets derived from Genome Therapeutics' PathoGenome Database

Replacing their 1998 agreement, they significantly increased commitment of shared, dedicated scientific and technical resources; includes joint ownership rights to all lead compounds and resulting commercial outcomes

Array Biopharma Inc.

Immunex Corp. (IMNX)

Non-exclusive agreement/Immunex granted access to Array's small-molecule libraries for screening against Immunex's high-throughput screening assays

Array retains exclusive option to enter into a lead-optimization agreement with Immunex to develop leads generated from this agreement

Athersys Inc.

Molecumetrics Ltd. (subsidiary of Tredegar Corp; NYSE:TG)

Development collaboration/Athersys will use its Rage-VT technology to provide Molecumetrics with 12 cell lines expressing validated targets; Molecumetrics will use its chemistry-based “screen-to-IND“ technology to develop novel small- molecule drug candidates against these targets

Both companies will co-invest in particular projects and share in the downstream value of the collaboration

Atrix Laboratories Inc. (ATRX)

Geneva Pharmaceuticals (subsidiary of Novartis AG; NYSE:NVS)

Development and manufacturing agreement/Broad collaborative agreement with Geneva to develop and manufacture prescription generic dermatology products

A targeted number of products will be developed by Atrix over a 10-year period; Geneva will market the products under a profit-sharing agreement

Aviron Inc. (AVIR)

Evans Vaccines Ltd. (unit of PowderJect Pharmaceuticals plc; UK; LSE:PJP)

Renegotiated manufacturing agreement/FluMist will continue to be manufactured at Evans Vaccines' Speke site in a dedicated production unit now leased to Aviron

Aviron will make initial payments to PowderJect totaling $15M, with further payment of $4M per year for 5 years and milestone payments up to $3M; PowderJect will receive warrants for 63,162 shares of Aviron common stock

AxCell Biosciences Corp. (subsidiary of Cytogen Corp.; CYTO)

Molecular Staging Inc.

Collaborative investigation/Determine potential synergies between AxCell's domain-ligand interaction technology and MSI's protein arrays to map protein pathways more rapidly and efficiently

ND

Biota Holdings Ltd. (Australia; ASX:BTA)

Vapotronics Ltd. (subsidiary of Vapotronics Inc.)

Evaluation agreement/Agreement to research the effectiveness of Vapotronics' aerosol applications for one or more of Biota's drugs

ND

Biovation Ltd. (Scotland)

Procyon BioPharma Inc. (Canada; TSE:PBP)

Development/Develop chimeric and de-immunized ANA therapeutic monoclonal antibodies for therapeutic, diagnostic and vaccine products to accelerate Procyon's ANA technology

The companies signed a letter of intent for a definitive agreement to be in place within 30 days, which will include specific details regarding development plans, milestones, deliverables, and contractual obligations

British Biotech plc (UK; BBIOY)

Serono S.A. (Switzerland; SWX:SEO)

Research, development and commercialization agreement/The companies have an exclusive agreement to jointly research, develop and commercialize metalloenzyme inhibitors (MEIs) for the treatment of serious inflammatory diseases

There is an option for Serono to obtain exclusive rights to develop and commercialize BB-2827 following completion of certain clinical studies by British Biotech; Serono also gains rights to BB-76163

Cambridge Antibody Technologies plc (UK; LSE:CAT)

Human Genome Sciences Inc. (HGSI)

Research collaboration/Use of CAT's technology to develop an unlimited number of fully human antibodies for therapeutic and diagnostic purposes

Extension of original collaboration (2/00 and 8/99) to include an exclusive development partnership on the target B-lymphocyte stimulator; CAT will receive license fees, clinical development milestones and royalties on sales; financial details were not disclosed

Ceres Inc.

Aurora Biosciences Corp. (ABSC)

Licensing, development and service agreement/Aurora's green fluorescent protein technology non-exclusive license granted to Ceres for use in in vitro and in vivo research and development activities and to provide selected services to third parties

Aurora gets up-front technology access fee, annual license fees and royalties on services provided to third parties; Aurora also has an option to acquire equity in Ceres

Chiron Corp. (CHIR)

EntreMed Inc. (ENMD)

Manufacturing agreement/Chiron will continue production of EntreMed's bulk Endostatin protein for EntreMed's Phase II clinical trials

The agreement was extended to 2001

Cobra Therapeutics Ltd. (subsidiary of ML Laboratories)

Coulter Pharmaceutical Inc. (CLTR)

Collaborative agreement/Cobra and Coulter jointly develop and commercialize Cobra's platform gene expression technology

Coulter will pay Cobra an up-front payment of #1M (US$1.5M) and event- based milestone and sublicense fees

CuraGen Corp. (CRGN)

Gemini Genomics (GMNI)

Drug target discovery collaboration/Application of CuraGen's PathCalling proteomic technology for ascertaining the biological disease-associated genes, building upon a prior collaborative research agreement

The companies will jointly own resulting intellectual property, with the intent to license small-molecule drug target discoveries; potential therapeutic proteins and antibody targets will be entered into CuraGen's product development programs for various diseases

Discovery Partners International Inc. (DPII)

Maxia Pharmaceuticals Inc.

Development and production agreement/Discovery Partners will help design and synthesize compounds for use in Maxia's research and development programs

Maxia will have exclusive rights to develop and commercialize all resulting compounds; financial terms were not disclosed

Ecopia Biosciences Inc. (TSE:EIA)

Kosan BioSciences Inc. (KOSN)

Research and license agreement/Ecopia will apply its genomics platform to discover genes responsible for directing the synthesis of an unnamed small molecule of interest to Kosan

The term of the agreement is six months or less; financial terms were not disclosed

Elan Corp. plc (Ireland; NYSE:ELN)

Neurome Inc.

Research partnership/Neurome will use its technologies to analyze Elan's mouse model of Alzheimer's disease for molecules and pathways to exploit for diagnostics and treatment

The term of the partnership is for three years; Neurome may receive up to $4M in service revenue, along with shared ownership of the resulting diagnostic and therapeutic applications

EyeTech Pharmaceuticals Inc.

Iomed Inc. (IOX)

Development collaboration/Companies will develop a non-invasive drug delivery system for EyeTech's investigational, anti-angiogenesis therapy EYE001, targeting age-related macular degeneration

EYE001 will be tested in Iomed's OcuPhor non-invasive transscleral delivery system for active drug transport to the retina and sub-retinal eye tissues; financial terms were not disclosed

Genomic Solutions Inc. (GNSL)

Research Genetics (division of Invitrogen Inc.; IVGN)

Collaborative agreement/Genomic Solutions gains access to Research Genetics' human, rat and mouse gene libraries for printing on Genomic's GeneMAP cancer microarrays

This agreement allows Genomics to expand its GeneMAP product line and an opportunity for Research Genetics to market to Genomic's customers; it also covers any libraries that Research Genetics may offer in the future

Genzyme Molecular Oncology (GZMO)

Invitrogen Corp. (IVGN)

Exclusive licensing agreement/ Invitrogen was granted exclusive worldwide rights to sell Genzyme's patented SAGE genomics technology in standardized reagent kits

Genzyme will receive up-front payment and royalties on sales of each SAGE kit; Invitrogen will also be allowed to distribute Genzyme's proprietary bioinformatics software for analysis of SAGE results

Heska Corp. (HSKA)

Valentis Inc. (VLTS)

License agreement/Heska received rights to Valentis' gene delivery and DNA manufacturing technology to complete development of a novel gene medicine for canine cancer treatment

Specific terms, which include an up-front license fee, milestone payments and royalties, were not disclosed

HTS Biosystems Inc.

Boston Probes and Applied Biosystems Inc. (NYSE:PEB)

Licensing, development and service agreement/Aurora's green fluorescent protein technology non-exclusive license granted to Ceres for use in in vitro and in vivo research and development activities and to provide selected services to third parties

Boston Probes will receive an up-front fee, maintenance fees and royalties from product sales

Immuno-Designed Molecules SA (France)

Medarex Inc. (MEDX)

Immuno-Designed Molecules (IDM) acquired worldwide rights to use of Medarex's MDX-210 anti-HER2 product in cell therapy, with certain rights to MDX-220 and MDX-447 for use in any field

IDM has also acquired the right to receive royalty payments from third party sales in Europe of MDX-210, outside the field of cell therapy; through this transaction, Medarex increased its interest in IDM from 6% to approximately 34%

ImmunoGen Inc. (IMGN)

MorphoSys AG (Germany)

Development/Companies will collaborate on development of human antibodies for cancer treatment

MorphoSys will receive a technology access payment, as well as development-related milestone payments and royalties on marketed products; financial terms were not disclosed

Lexicon Genetics Inc. (LEXG)

Tularik Inc. (TLRK)

Multi-year research agreement/Tularik will have access to conditional and gene-specific knockouts with genetic alterations directed at specific Tularik drug targets from Lexicon's OmniBank Internet Universal gene targeting program, and have access to the OmniBank library of 90,000 knockout mouse clones for use in determining gene function

ND

Luminex Corp. (LMNX)

Upstate Biotechnology

Strategic partnership to develop reagents and assay kits for basic research and drug discovery applications based on Luminex's LabMAP technology, complementing Upstate's cell-signaling reagents and assay kits for basic research and drug discovery

ND

Lynx Therapeutics Inc. (LYNX)

Molecular Engines Laboratories SA (France)

Research collaboration/The companies signed a two-year research collaboration for Lynx to apply its Megasort technology to cancer cell lines provided by Molecular Engines to identify differentially expressed genes to revert malignant cells to non-malignant cells

Molecular Engines plans to incorporate the findings into its overall tumor research; Lynx will receive payments for genomic discovery services and royalty payments for any resulting products or services; other financial terms were not disclosed

Maxygen Inc. (MAXY)

SIGA Technologies Inc. (SIGA)

Research collaboration/The companies will develop novel vaccines using SIGA's vaccine delivery system and Maxygen's antigens to generate an immune response at mucosal surfaces

ND

Mirus Inc.

Transgene SA (France; TRGNY)

Research and licensing agreement/Using Mirus' muscle delivery technology and Transgene's plasmid- based and adenoviral vectors to develop gene therapy products for muscular dystrophy and multiple sclerosis

Transgene will fund a one-year research program at Mirus, applying the technologies to deliver the therapeutics to skeletal muscle

MolSoft LLC

Syrrx Inc.

Strategic alliance/10-year alliance to accelerate structure-guided drug discovery using MolSoft's Virtual Ligand Screening (VLS) technology with Syrrx's high-throughput structural proteomics platform

Syrrx will be the only company authorized to use MolSoft's VLS technology in combination with structural proteomics capabilities; however, MolSoft will continue to provide VLS services directly to other companies

Morphochem AG (Germany)

Synt:em Inc. (France)

Discovery and development agreement/Companies entered a flexible framework collaboration using Synt:em's computational platform and Morphochem's chemical entity libraries, with the first project to focus on antiviral compound discovery

Companies will share contribution and benefits to co-discover, co-validate and co-develop products up to clinical trials; financial details were not disclosed

Orchid BioSciences Inc. (ORCH)

DNAPrint Genomics Inc. (Pink Sheets:DNAP)

License/Orchid received an option to license rights to co-develop and/or co-commercialize certain existing or future DNAPrint products and intellectual properties

The option provides Orchid exclusive rights to negotiate partnership terms with DNAPrint for these products and properties; other terms were not disclosed

PhycoGen Inc.

Trega Biosciences Inc. (TRGA)

Service agreement/Trega provides its Chem.Folio chemistry services to PhycoGen for use in discovery programs that involve biological cell-adhesion processes

Trega will receive up-front and milestone payments in exchange for the design and synthesis of custom compounds according to Phytogen's specificiations; additional financial terms were not disclosed

Sangamo BioSciences Inc. (SGMO)

Artemis Pharmaceuticals GmbH and Exelixis Inc. (EXEL)

Development collaboration/Combine Artemis' Conditional knockout expertise with Sangamo's ZFP technology to produce an advanced modeling system using a new way to produce knockout mice for functional gene validation

ND

Sequenom Inc. (SQNM)

Incyte Genomics Inc. (INCY)

Research collaboration and commercialization agreement/Incyte licenses single nucleotide polymorphisms (SNPs) to Sequenom for analysis and validation and Sequenom provides Incyte with access to its MassARRAY technology and proprietary marker validation strategies to create validated SNP assays for use in genetic research

Sequenom will use the validated SNP information to develop and market 100,000 SNP assays, or tests for genetic markers, and will screen the SNPs against its in-house reference human DNA bank; they agreed to jointly commercialize the resulting intellectual property and expect to form partnerships for downstream product development; financial terms were not disclosed

Third Wave Technologies Inc.

Epoch Biosciences (EBIO)

Development, licensing and supply agreement/Epoch will develop, license and supply certain proprietary technol- ogies for Third Wave's Invader operating system for genetic analysis, and will provide certain access to certain fluorescent dye chemistries

Third Wave will fund certain development activities at Epoch and will have an option to license Epoch's proprietary minor groove binder and modified base technologies

ZymoGenetics Inc. (unit of Novo Nordisk A/S; Denmark)

Medarex Inc. (MEDX)

Development agreement/Combining Medarex's fully human monoclonal antibody development technology and ZymoGenetics' expertise in the genomics field and protein therapeutics to create antibodies to ZymoGenetics-identified multiple disease targets

ZymoGenetics is responsible for the development and commercialization of human antibodies products resulting from the alliance; Medarex expects to receive license fees and milestone payments, as well as royalties on resulting sales

September - 2000

Company

Company

Type/Product Area

Terms/Details

Affymetrix Inc. (AFFX)

Lexicon Genetics Inc. (LEXG)

Supply agreement/Lexicon obtains Affymetrix's GeneChip technology for its internal drug discovery program

ND

AntexPharma (subsidiary of Antex Biologics Inc.; AMEX:ANX)

Lyotropic Therapeutics LLC

Collaboration to formulate AntexPharma's antibiotic candidates with the LyoCell drug delivery system

ND

AnVil Informatics Inc.

PolyGenyx Inc.

Bioinformatics/AnVil initially will build a database suitable of hosting the large amount of data originating from PolyGenyx's laboratory in Worcester, Mass.

The companies are also in discussion for a longer-term collaboration on data- exploration projects

Applied Molecular Evolution Inc. (AMEV)

Idexx Laboratories Inc. (IDXX)

License/Development of diagnostic applications under Applied Molecular's Kauffman patents

License is non-exclusive

Biolog Inc.

Paradigm Genetics Inc. (PDGM)

Licensing agreement/Biolog licensed its Phenotype MicroArray to Paradigm, who will use the technology to determine gene function in agriculturally important fungal species

The multi-year agreement gives Paradigm non-exclusive rights to the products

BioStar Inc.

Agouron Pharmaceuticals Inc.

Non-exclusive license/BioStar granted Agouron rights to itstechnology for optical detection of nucleic acids

Amendment of a previous agreement

Biozhem Cosmeceuticals Inc. (OTC BB:BZHM)

Advanced Tissue Sciences (ATIS)

License and Supply agreement/Biozhem obtains exclusive marketing rights to skin care products containing ATS nutrient solution

Financial terms of the agreement were not disclosed

Celera Genomics

ValiGen NV

Subscription/ValiGen gets a five-year subscription to Celera's integrated database products, bioinformatics systems and other discovery tools

ND

Cytogen Corp. (CYTO)

Draxis Health Inc. (DRAX)

Marketing/Draxis' BrachySeed implant for treating local cancers, especially prostate cancer

Cytogen will pay milestones and royalties

Eos Biotechnology Inc.

Biogen Inc. (BGEN)

Research and development/ identification of targets for antibody and protein therapeutics in the area of breast cancer

Value of the collaboration to Eos could reach $55M, not including royalties on sales of products identified through the collaboration

Gene Logic Inc. (GLGC)

Amersham Pharmacia Biotech K.K. (Japan)

Distribution agreement/Amersham obtained exclusive distribution rights to Gene Logic's products for the Japanese pharmaceutical and biotech market

Financial terms were not disclosed. Products included in the distribution agreement are the GeneExpress Suite, gene expression databases and data management tools and applications

Genzyme General (GENZ)

Cambridge Antibody Technology (LSE:CAT)

Strategic alliance/Genzyme and CAT will merge their efforts at commercializing human monoclonal antibodies against TGF-beta

Revenue sharing, Genzyme makes a $20M equity investment in CAT. Resultant small molecules licensed to Genzyme for milestones, royalties. Ophthalmic indications excluded, remain CAT's

Genome Therapeutics Corp. (GENE)

Genomica Corp.

Licensing agreement/Genomica licensed its Discovery Manager software to Genome Therapeutics

ND

Genomica Corp.

PE Biosystems (NYSE:PEB)

License/Genomica's comprehensive genetic-analysis object model

License details ND; separately, Applied agreed to invest $3M in Genomica equity

Genta Inc. (GNTA)

Oasis Biosciences Inc.

Non-exclusive licensing agreement/Genta licensed its anitsense patents to Oasis

Upfront payments from Oasis in cash and royalties on product sales

Genzyme Molecular Oncology (GSMO)

Celera Genomics (NYSE:CRA)

Co-exclusive worldwide marketing agreement/Celera obtained rights to market Genzyme's SAGE database to Celera customers

Revenue sharing

Hybrigenics SA (France)

XTL Biopharmaceuticals Ltd.

Research and development/Development of drugs against hepatitis C virus; Hybrigenics will select potential drug targets using its PIMRider technology, and XTL will validate the targets and corresponding therapeutics for efficacy using cell-based assays and the company's Trimera mouse model of HCV infection

Each party will retain an equal interest in products developed; companies plan to jointly fund development through Phase II trials; Hybrigenics granted XTL a non-exclusive license to its PIMRider technology database, for use in XTL's other research programs

Isis Pharmaceutical Inc. (ISIP)

Pantheco A/S (Denmark)

Licensing agreement/Pantheco licensed from Isis a third generation antisense chemistry, Peptide Nucleic Acid, to treat diabetes and cardiovascular diseases;

Pantheco will pay $1.1M license fee payable Pantheco shares, plus royalties and milestone payments on products developed; this is the second license of PNA technology from Isis to Pantheco; Isis' stake in Pantheco will be approximately 21%.

Lexicon Genetics Inc. (LEXG)

Biogen Inc. (BGEN)

License/Certain aspects of Lexicon's positive-negative selection technology for the generation of knockout mice

License is non-exclusive

Minerva Pharmaceuticals Inc.

Diagnostic Products Corp.

License/Development of immunoassays for a malignancy protein

ND

Novartis Pharma AG

BioTransplant Inc. (BTRN)

Joint venture/Novartis and BioTransplant created a xenotransplantation company to move that process to the clinic. The new company will be based in Boston and begin operation Jan. 1, 2001, headed by BioTransplant Chief Scientific Officer Julia Greenstein

Novartis will own 67 percent of the new company, and BioTransplant will own 33 percent. Novartis retains commercialization rights to products the company produces, and BioTransplant will receive royalties on those sales

NsGene A/S (Denmark)

Ariad Pharmaceuticals Inc. (ARIA)

Research collaboration/Companies will combine Ariad's Regulated Gene Expression Technology with NsGene's neurotrophic factors and technologies for culturing and engineering neural cells and delivering them to the central nervous system

After initial research phase, further development and commercial terms will be determined

Orchid BioSciences Inc. (ORCH)

Tecan (Switzerland)

Supply/Tecan will supply Orchid with systems solutiosn for DNA processing

Agreement is non-exclusive

Oxford Biomedica plc (UK)

InforMax Inc.

Oxford BioMedica will access InforMax's GenoMax and Vector NTI suites for use in analyzing and interpreting genomics data from Oxford's Gene Discovery Divsion

Discussions between the companies over joint marketing resultant genetic information are ongoing. BioMedica retains full commercial licensing rights to the genes and products rising from them

Oxford GlycoSciences plc (UK; LSE:OGS)

Medarex Inc. (MEDX)

Research and development/Use of Medarex's technology to generate human monoclonal antibodies to up to 30 OGS targets

Medarex will make a $5M equity investment in OGS; companies will share preclinical and clinical responsibilities

Oxford GlycoSciences plc (UK; LSE:OXB)

Packard BioScience Co. (PBSC)

Development collaboration/Development of protein biochips

ND

PolyGenyx

Genomics Collaborative

Research collaboration/Application of PolyGenyx's high-throughput HaploScan technology to single nucleotide polymorphism haplotyping

ND

PolyMASC Pharmaceuticals plc (subsidiary of Valentis; VLTS)

Viragen Inc. (AMEX:VRA)

Research and development/Use of PolyMASC's protoMASC PEGylation process to deliver Viragen's lead drug, Omniferon, a natural alpha interferon currently in Phase II trials

ND

Questcor Pharmaceuticals Inc. (AMEX:QSC)

Rigel Pharmaceuticals Inc.

Exclusive licensing agreement/Questcor granted rights to antiviral drug research technology to Rigel, who will use the technology for Hepatitis C drug discovery and development

Undisclosed cash payment from Rigel to Questcor, an undisclosed amount of Rigel stock and future milestone and royalty payments for Questcor

Rigel Pharmaceuticals Inc.

Cytomation Inc.

Collaborative agreement/Rigel and Cytomation will combine technologies for drug target discovery

ND

Sangamo BioSciences Inc. (SGMO)

Rosetta Inpharmatics Inc. (RSTA)

Joint research agreement/Sangamo and Rosetta will apply their technologies to perform functional genomics study on potential therapeutic targets

Each company will fund its own efforts

Sequiter Inc.

Vertex Pharmaceuticals Inc.

Supply agreement/Sequiter agreed to provide Vertex with access to its antisense functional genomics technology and a supply of antisense compounds

Financial terms were not disclosed

Structural Bioinformatics Inc.

InforMax Inc.

Marketing/InforMax will offer SBI's database content of atomic resolution 3-D protein models to GenoMax customers

ND

August - 2000

Company

Company

Type/Product Area

Terms/Details

Abgenix Inc. (ABGX)

SangStat Medical Corp. (SANG)

License, co-development and supply agreement/Abgenix's ABX-CBL, an anti-CD147 antibody for the treatment of steroid-resistant graft-vs.-host disease

SangStat acquired an exclusive worldwide license to ABX-CBL and will have the right to commercialize other anti-CD147 antibodies; SangStat will make an initial license fee payment and additional milestone payments; companies will share development costs and responsibilities, and will equally share any potential profits

Adherex Technologies Inc. (Canada)

BioChem Pharma Inc. (BCHE)

Development collaboration/Development of Adherex's anticancer agent Exherin, which targets the adhesion system blood vessels use to connect to each other

BioChem may pay up to $25.5M in milestones and purchase of an equity stake in Adherex, in addition to sales revenues

Affymetrix Inc. (AFFX)

deCode Genetics Inc. (DCGN)

Technology access/Access to Affymetrix's standard GeneChip arrays, instrumentation and software to monitor gene expression

Access granted under Affymetrix's BiotechAccess plan for biotechnology companies

Altea Genomics Inc.

Elan Corp. plc (Ireland; NYSE:ELN)

Joint venture/Development of up to five products using Altea's non-invasive MicroPor technology and Elan's formulation technology; the primary focus is DNA vaccines and gene therapy

In some situations, Elan will market resulting products, but for others, third-party pharmaceutical partners will be sought

AMBI Inc. (AMBI)

Biosynexus Inc.

License/AMBI's nisin and lysostaphin antibacterial technologies

AMBI will receive $1.4M up front, plus future milestone payments of $14M, royalties upon commercialization of products resulting from the technology, warrants to AMBI for the purchase of Biosynexus shares, and potential other consideration based on agreements between Biosynexus and third parties

Array BioPharma

Icos Corp. (ICOS)

Research collaboration and process research and manufacturing/Array optimizes leads for Icos targets

Companies expanded 2/99 agreement and entered a new process research and manufacturing agreement; Icos will provide funding to Array and make milsetone payments

Arena Pharmaceuticals (ARNA)

Lexicon Genetics Inc. (LEXG)

Research collaboration/Discovery of compounds that target G protein-coupled receptors

Lexicon and Arena will contribute equal numbers GPCRs to be validated; each company will share equally in up-front fees, milestones and royalties generated from products; companies may agree to jointly fund development of compounds, although both companies intend to partner the majority of the drug targets

Athersys Inc.

Medarex Inc. (MEDX)

Research collaboration/Use of Athersys RAGE technology for discovering therapeutic targets and Medarex's Hu-MAb Mouse technology for generating fully human monoclonal antibodies

Companies will share preclinical and clinical responsibilities, and jiontly commercialize resulting products; additionally, Athersys has an option to obtain access to Medarex's HuMAb technology for targets outside the collaboration, and Medarex has an option for access to validated therapeutic targets produced with RAGE-VT; Medarex also made an investment in Athersys

Biogen Inc. (BGEN)

Elan Corp. plc (Ireland; NYSE:ELN)

Development collaboration/Antegren (natalizumab), a humanized monoclonal antibody nearing the completion of Phase II testing

Companies will share costs for ongoing development activities and economic benefits; terms include up-front and milestone payments

BioSante Pharmaceuticals Inc. (OTC BB:BTPH)

Antex Biologics Inc. (AMEX:ANX)

Option license/Development of BioSante's calcium phosphate nanoparticle platform technology as an adjuvant in vaccines against Chlamydia and Helicobacter pylori

BioSante will formulate vaccines using CAP and Antex's antigens for testing by Antex in animal models; in addition to the research collaboration, BioSante has granted to Antex an option to a worldwide non-exclusive license to use CAP in Chlamydia and H. pylori vaccines that may be developed for human use by Antex

Cytogen Corp. (CYTO)

Northwest Biotherapeutics Inc.

Agreement clarifying rights/Use of prostate specific membrane antigen

ND

De Novo Pharmaceuticals Ltd. (UK)

British Biotech (UK; LSE:BBG)

Research collaboration/Use of De Novo's expertise and platform of computer algorithms to provide novel small-molecule antibacterial leads

British Biotech made an up-front payment and will provide 12 months of research funding

Enchira Biotechnology Corp. (ENBC)

Genencor International (GCOR)

ND

Companies signed a follow-on to their 5/00 agreement under which Genencor gained access to Enchira technology for developing gene-based products; new agreement involves Enchira's RACHITT gene-shuffling technology to build libraries of hybrid genes for pharmaceutical, agricultural and industrial sectors

Epoch Biosciences

PE Biosystems (NYSE:PEB)

Technology collaboration/Incorporation of Epoch's technology (including minor groove binding technology) in the entire line of Applied Biosystems TaqMan reagent products

Expansion of relationship from limited licensing agreement to strategic alliance; Applied Biosystems will market the new probes and will fund research at Epoch and pay supplemental license fees; Epoch will manufacture a apecified portion of the new probes

EPPTCO Inc. (UK)

Onyx Pharmaceuticals Inc. (ONXX)

Research collaboration/Prodrugs converted by the enzyme nitroreductase into cytotoxic anticancer agents

Onyx gains access to the gene encoding the enzyme, plus rights to license, on an exclusive basis, worldwide rights to prodrgs discovered through the collaboration for use in Onyx's selectively replicating armed therapeutic virus system

Eukarion Inc.

KS Biomedix Holdings plc (UK)

Research and development collaboration/Use of Eukarion's antibody lipidation and chemical modification technologies to enable KS's super-high-affinity sheep monoclonal antibodies to be used against novel disease targets

ND

Eurogene Ltd. (UK)

Valentis Inc. (VLTS)

Research collaboration/Development of a nitric oxide synthase gene medicine for the prevention or treatment of restenosis following bypass graft surgery; combines Valentis' gene formulation and expression technologies with Eurogene's extravascular delivery collar

Companies will share costs and revenues in this second collaboration beween the two

Eurogene Ltd. (UK)

Valentis Inc. (VLTS)

Research collaboration/Nitric oxide synthase gene medicine for prevention of restenosis; product development will combine Valentis' gene formulation and expression technologies and Eurogene's extravascular delivery collar

Companies will share research and development costs and potential revenues

FamilyGenetix Ltd. (formerly Cherwell Scientific Ltd.)

NetGenics Inc.

Software acquisition/NetGenics acquired FamilyGenetix's ChemSymphony and MetaSymphony software programs

NetGenics paid $1M to acquire the software

Flemington Pharmaceutical Corp.

PolyMASC Pharmaceuticals plc (subsidiary of Valentis Inc.; VLTS)

Research collaboration/Development of a pegylated formulation of insulin delivered by Flemigton's Immediate-Immediate Release lingual spray system

Each party will be responsible for its own development costs; if feasibility studies are successful, the companies intend to seek a corporate partner for development and marketing

Gene Tec Corp.

Applied Biosystems Group (unit of PE Corp.; NYSE:PEB)

License/Gene Tec's method of amplifying nucleic acid targets directly in cells and viruses

License is non-exclusive; PE will pay royalties for the kits and instruments it sells for use with in situ polymerase chain reaction

Genome Therapeutics Corp. (GENE)

Compugen Inc. (CGEN)

Database access/Addition of Genome Therapeutics' PathoGenome database of pathogen sequence information to Compugen's LabOnWeb.com portal

Data can be accessed on pay-per-view basis

Genomics Collaborative Inc.

Lynx Therapeutics Inc. (LYNX)

Research collaboration/Use of Genomics Collaborative's DNA samples genome-wide scan for single-nucleotide polymorphisms associated with Type 2 diabetes

ND

Genomics Collaborative Inc.

Genometrix Inc.

Research collaboration/Analysis of clinically characterized DNA samples for profiling single nucleotide polymorphism in patients with hypertension

The companies will independently commercialize any diagnostic or therapeutic applications resulting from the collaboration

Genzyme Molecular Oncology (GZMO)

Myriad Genetics Inc. (MYGN)

License/Genzyme's cancer diagnostic patent rights related to an undisclosed gene implicated in hereditary colon cancer; Myriad is launching a test called Colaris based on teh gene in 9/00

Genzyme received an up-front payment and will receive royalties on each Colaris test performed

Geospiza Inc.

DNAPrint genomics

Testing/DNAPrint will participate in beta-testing of Geospiza's DNA sequence information management system for standard DNA sequencing files

License is extendable

Luminex Corp. (LMNX)

Life Technologies (OTC BB:LTEK)

Marketing/Life will market reagents and instrumentation based on Luminex's LabMAP technology

Life receives worldwide non-exclusive rights in exchange for an up-front payment and future royalties

Medarex Inc. (MEDX)

Genencor International Inc. (GCOR)

Expansion of license agreement; rights under Medarex patents to develop, generate and use mice with transplanted human cells for research and development of commercial non-antibody therapeutic products

Expansion of 1988 agreement originally signed with GenPharm International, now a wholly owned subisidiary of Medarex

Medarex Inc. (MEDX)

Genencor International Inc. (GCOR)

Expansion of license agreement; rights under Medarex patents to develop, generate and use mice with transplanted human cells for research and development of commercial non-antibody therapeutic products

Expansion of 1988 agreement originally signed with GenPharm International, now a wholly owned subisidiary of Medarex

Molecular Simulations Inc. (subsidiary of Pharmacopeia Inc.; PCOP)

Cytoclonal Pharmaceutics Inc. (CYPH)

Consortium membership/Cytoclonal joined MSI's Functional Genomics Consortium, gaining access to GeneAtlas, a collection of functional annotations, and AtlasBase, a collection of available gene sequences with enhanced functional annotations

ND

Molecular Simulations Inc. (subsidiary of Pharmacopeia Inc.; PCOP)

Hyseq Inc. (HYSQ)

Consortium membership/Hyseq joined MSI's Functional Genomics Consortium, gaining access to GeneAtlas, a collection of functional annotations, and AtlasBase, a collection of available gene sequences with enhanced functional annotations

ND

Iconix Pharmaceuticals Inc.

Motorola's BioChip Systems unit (unit of Motorola; NYSE:MOT)

Database collaboration/Creation of a chemical genomic database; Iconix will validate the beta release of Motorola's new CodeLink Expression System and become one of the first high-volume users

Motorola made an equity investment in Iconix and received rights to distribute the resulting Iconix ChemExpress database as part of future BioChip System solutions

Nanoscale Combinatorial Synthesis Inc.

ArQule Inc. (ARQL)

Technology evaluation and chemistry services/Nanoscale will perform custom chemical synthesis projects that will enable ArQule to evaluate the Accelerated Nanoscale Synthesis Technology sSystem

ArQule will provide project funding for up to two years

NeoRx Corp. (NERX)

Nexell Therapeutics Inc. (NEXL)

License/In vitro diagnostic applications of the NRLU-5 antibody, a cell surface marker common to many tumor types

ND

Novelos Therapeutics Inc.

Phytera Inc.

License/Novelos' BAM-002, a Phase I/II stage anticancer drug

Phytera acquired North American rights

NPS Allelix (subsidiary of NPS Pharmaceuticals Inc.; NPSP)

ICAgen Inc.

License/NPS Allelix's nervous system specific sodium channel gene technology

ND

NsGene A/S (Denmark)

Neurotech SA (France)

Research collaboration and license/Use of Neurotech's Encapsulated Cell Technology to treat neurological and eye disorders; Neurotech also gains rights to use NsGene's neurotrophic factor Neublastin for eye indications in combination with ECT

NsGene paid Neurotech an up-front fee, and both parties will receive cross royalties on net revenues for products developed by either party

Oxford Molecular Group (UK; LSE:OMG)

Pharmacopeia Inc. (PCOP)

Purchase/Pharmacopeia will acquire OMG's software subsidiaries

Pharmacopeia will pay $27M in cash and assumption of liabilities; deal requires OMG shareholder approval and is expected to close 8/00

Pharming Group NV (the Netherlands)

Genencor International Inc. (GCOR)

License/Rights under Pharming's patents covering the insertion of greater than 50 kb DNA into a mammalian cell or animal, which can be used to introduce human genes into a mouse

ND

SignalGene Inc. (Canada; TSE:SGI)

Anapharm Inc.

Services/SignalGene will provide pharmacogenomics services

Phytera acquired North American rights

Talon Cheminformatics Inc. (Canada)

Mycota Biosciences Inc. (Canada)

Compound library purchase/Mycota purchased a library of 20,000 compounds for screening

Purchase

Targeted Genetics Corp. (TGEN)

Biogen Inc. (BGEN)

Development and commercialization collaboration/Development of gene therapy products

Collaboration worth up to $125M replaces and expands 1995 agreement between Biogen and Genovo (which Targeted Genetics is acquiring); Biogen will pay $8M up front, provide research and development funding, and make milestone payments and a $10M equity investment

Xenogen Corp.

Cubist Pharmaceuticals Inc. (CBST)

Evaluation/Use of Xenogen's real-time in vivo imaging technologies in preclinical evaluation of new antimicrobial agents

ND

July - 2000

Company

Company

Type/Product Area

Terms/Details

Abgenix Inc. (ABGX)

Immunex Corp. (IMNX)

Development collaboration/ABX-EGF, a fully human antibody created by Abgenix and currently in a Phase I trial involving several tumor types

Immunex will make an initial license fee payment to Abgenix and a second license fee payment upon commencement of Phase II trials; development costs and profits will be shared equally; Abgenix will complete the ongoing Phase I trial, and companies will share Phase III efforts; Immunex will have primary responsibility for Phase III trials and would market the product, while Abgenix would retain co-promotion rights

Affymetrix Inc. (AFFX)

Deltagen Inc. (DGEN)

Technology access/Deltagen will use Affymetrix's GeneChip probe arrays to build and commercialize DeltaXpress databases of gene expression information utilizing Deltagen's knockout mouse models

Deltagen will pay Affymetrix annual subscription fees for access to GeneChip technology, purchase probe arrays and related instrumentation and software, and pay royalties on database subscription fees

Arena Pharmaceuticals (ARNA)

Lexicon Genetics Inc. (LEXG)

Research collaboration/Discovery of compounds that target G protein-coupled receptors

Lexicon and Arena will contribute equal numbers GPCRs to be validated; each company will share equally in up-front fees, milestones and royalties generated from products; companies may agree to jointly fund development of compounds, although both companies intend to partner the majority of the drug targets

Arrow Therapeutics Ltd. (UK)

Triangle Pharmaceuticals Inc. (VIRS)

Research collaboration/Arrow will contribute an antiviral target, high-throughput screening technology and a compound library; Triangle will provide preclinical and clinical development

Triangle will cover up-front research funding and will make contingent development milestone payments, as well as paying royalties on sales

Avigen Inc. (AVGN)

Stratagene (France)

License agreement/Stratagene will sell kits using Avigen's recombinant adeno-associated virus vectors for research purposees

Avigen will receive an up-front payment and royalties on sales, plus rights to all AAV technologies and intellectual property developed by Stratagene

Diversa Corp. (DVSA)

Invitrogen Corp. (IVGN)

License agreement/Invitrogen will commercialize three of Diversa's thermostable RNA-modifying enzymes for the molecular biology research market

Diversa will receive royalties and retain rights for the enzymes in the diagnostics market

Elitra Pharmaceuticals Inc.

Incyte Genomics Inc. (INCY)

Database collaboration/Use of Incyte's PathoSeq microbial sequence database technologies

Elitra will use PathoSeq as a platform for its functional genomics programs and has the right to market and sell the database to third parties in collaboration with Incyte; Incyte will receive equity in Elitra

EraGen Biosciences

TimeLogic Corp.

Development and marketing/Tools for managing high-throughput sequence analysis

Both companies will promote each other's technologies through the creation of a channel partnership

FibroGen Inc.

ZymoGenetics Inc. (unit of Novo Nordisk A/S; Denmark; NYSE:NVO)

Research collaboration/Tissue sealant products for wound management combining FibroGen's recombinant human type III collagen and ZymoGenetics' recombinant human thrombin

ND

Fluorous Technologies Inc.

Albany Molecular Research Inc. (AMRI)

Equity investment/Use of fluorous organic chemistry technology for chemical synthesis, isolation and purification

AMRI invested $0.65M in Fluorous equity

Human Genome Sciences Inc. (HGSI)

Transgene (France; TRGNY)

License/Transgene selected two HGS genes for gene therapy development; the genes are AngioPro, an angiogenic factor with potential for treating peripheral and coronary artery disease, and VasoSten, a matrix metalloproteinase inhibitor for restenosis treatment and prevention

Under original 3/98 deal, Transgene has the right to license up to 10 genes for development as gene therapies; HGS receives milestone and royalty payments for each product

Lexicon Genetics Inc. (LEXG)

Abgenix Inc. (ABGX)

Research collaboration/Use of Abgenix's mouse technology to generate fully human monoclonal antibodies to Lexicon genetic targets

Each company will have the right to obtain exclusive commercialization rights for an equal number of antibodies; Lexicon and Abgenix will each receive milestone payments and royalties on sales of antibodies developed by the other company or through third-party sublicenses; each company will bear the expense of its own efforts

Life Technologies Inc. (now merged into Invitrogen Corp.; IVGN)

Celera Genomics (NYSE:CRA)

Database collaboration/Celera and Life will collaborate to create a large collection of clones of full-length human genes and the corresponding gene sequences

Celera will use the sequence information to annotate its database, and Life will sell the clones to database users

MediChem Research

Argonaut Technologies (AGNT)

Development collaboration/Methodology to speed chemical reaction optimization; combines parallel synthetic methods with statistical design of experiments software

Argonaut will distribute the integrated platform worldwide

Meditech Pharmaceuticals Inc. (OTC BB:MDCH)

Immune Network Research (VSE:IMM)

Exercise of license option/Two Meditech antiviral compounds, MTCH-24 and Viraplex

Immune Network gains a license worldwide, except for the U.S., and will pay an advance licensing fee of $0.1M, plus royalties of 4% to 7% of net product sales

MicroMed Technology Inc.

Chrysalis Biotechnology Inc.

Research collaboration/Evaluation of Chrysalin as a promoter of blood vessel regeneration in the heart

At the conclusion of 12-month evaluation period MicroMed will have the option to license Chrysalin for myocardial revascularization

Ontogeny Inc. (merged into Curis Inc.; CRIS)

Biogen Inc. (BGEN)

Return of rights/Development and commercialization of hedgehog protein products

Biogen returned rights gained in 1996 collaboration agreement worth up to $90M after a portfolio review

Orchid BioSciences Inc. (ORCH)

Millennium Pharmaceuticals Inc. (MLNM)

Service agreement/Orchid will score single nucleotide polymorphisms on samples provided by Millennium

ND

Orchid BioSciences Inc. (ORCH)

PE Biosystems (NYSE:PEB)

License/PE received a non-exclusive license to use Orchid's SNP-IT single-base primer extension technology for single nucleotide polymorphism analysis

PE will produce and market kits using the technology; terms ND

OrthoLogic Corp.

Chrysalis Biotechnology Inc.

License extension/Options for use of Chrysalin in orthopedic indications

OrthoLogic paid a $2M licensing fee in addition to milestone payments and royalties

UroCor Inc. (UCOR)

Immunex Corp. (IMNX)

License/Cancer-derived antigens

UroCor will receive an initial license fee, plus potential milestone and royalty payments

UroGenesys Inc.

Genentech Inc. (NYSE:DNA)

License/Development of antibody-based cancer therapeutics using prostate stem cell antigen as a target antigen

UroGenesys could receive milestone and other payments totaling $33M, plus royalties

June - 2000

Company

Company

Type/Product Area

Terms/Details

Active Biotech AB (Sweden; ACTIB)

Intellivax International Inc.

Development collaboration/Vaccine for prevention of infections with Group A, B-hemolytic streptococci

ND

Biosite Diagnostics Inc. (BSTE)

Medarex Inc. (MEDX)

Research collaboration/Development of a high-throughput method for creating fully human antibodies using phage display and mouse antibody technologies

Biosite will receive research funding of $3M per year for eight years, plus research fees, milestones and royalties; companies will seek third-partycollaborators

Affymetrix Inc. (AFFX)

MWG Biotech AG (Germany)

License/Use of certain Affymetrix intellectual property for commercializing low- and medium-density DNA arrays

MWG receives a non-exclusive, worldwide royalty-bearing license, allowing it to manufacture, use and sell the arrays in the research field; Affymetrix will receive fees and royalty payments

Alkermes Inc. (ALKS)

MedImmune Inc. (MEDI)

Research collaboration/Use of Alkermes' AIR pulmonary delivery technology to develop an inhalable formulation of a monoclonal antibody against respiratory syncytial virus

MedImmune receives an exclusive worldwide license to products and will pay initial fees, development funding, milestones, manufacturing fees and royalties on product sales

Alpha Therapeutic Corp.

National Genetics Institute

License/Use of a method of efficiently and rapidly testing large numbers of plasma donations for viruses using polymerase chain reaction technology

NGI gains exclusive license to use the method to provide services in the U.S., with the opportunity to expand to other countries

Atrix Laboratories (ATRX)

Elan Corp. plc (Ireland; NYSE:ELN)

Joint venture/Collaboration to develop oncology and pain management products using Atrix's BEMA and Atrigel delivery systems and Elan's NanoCrystal drug-delivery technology

Elan will provide funding to develop the compounds and will invest $5M in Atrix equity at a premium to market; Atrix will initially be the majority owner of the joint venture

Biomira Inc. (Canada; BIOM)

Chiron Corp. (CHIR)

Reacquisition of rights/Biomira's Theratope cancer vaccine

Biomira exercised an option to acquire Chiron's remaining rights to Theratope under the 1997 collaboration agreement between the two; Biomira will pay Chiron $2.25M, and upon approval of the product, will make a final payment of $3.25M, with no further obligation

BioSante Pharmaceuticals Inc. (OTC BB:BTPH)

ID Biomedical Corp. (IDBE)

License option/Development of BioSante's calcium phosphate nanoparticle core technology as an adjuvant for a vaccine against group-A streptococcus (StreptAvax)

ID has an option to a worldwide exclusive license to use the technology in Group-A streptococcus vaccines

Boston Probes Inc. (affiliate of Dako A/S; Denmark)

PE Biosystems (NYSE:PEB)

Cross-license/Development of products employing peptide nucleic acid technology, for which both companies have patents

PE acquired a minority equity stake in BPI

Celera Genomics (NYSE:CRA)

Immunex Corp. (IMNX)

Database access/Immunex gains access to four Celera databases -- the Human Gene Index, the Human Genome Database, the Drosophila Genome Database and the Mouse Genome Database

Five-year agreement; value estimated at between $25M and $50M

Connetics Inc. (CNCT)

InterMune Pharmaceuticals Inc. (ITMN)

License/Actimmune (interferon gamma-1b) injection for chronic granulomatous disease, osteoporosis, idiopathic pulmonary fibrosis and infectious diseases (FDA-approved and marketed by InterMune in the U.S.)

As part of InterMune's strategy to consolidate rights to Actimmune, it acquired from Connetics rights to Actimmune revenues it did not already own; InterMune paid Connetics $5.2M

Coelacanth Corp.

Microcide Pharmaceuticals Inc. (MCDE)

Screening collaboration/Use of Coelacanth's compound library in Microcide's anti-pathogen assays

Microcide has worldwide rights to develop compounds that emerge, and will pay Coelacanth milestones and royalties on any sales

Cortech Inc. (CRTQ)

United Therapeutics Corp. (UTHR)

License termination/United discontinued development of UT-77 (licensed in 1988 from Cortech) based on preclinical results and Phase II testing

ND

Cytovax Biotechnologies Inc.

BioChem Pharma Inc. (BCHE)

Development and license agreement/Use of Cytovax's Anti-Adhesion Platform Technology to develop a vaccine and monoclonal antibody therapy against infections caused by Pseudomonas aeruginosa

BioChem receives worldwide rights to develop, manufacture and market the vaccine and will provide research funding and expertise, and pay milestones and royalties on any products; BioChem is also purchasing an equity stake in Cytovax

DepoMed Inc. (AMEX:DMI)

AVI BioPharma Inc. (AVII)

Research collaboration/Collaboration to investigate the feasibility of controlled oral delivery of AVI's Neugene antisense agents using DepoMed's Gastric Retention system

Scientists from both companies will work on the feasibility project; further details ND

Diaclone SA (subsidiary of the Biotest Group; France)

Nexell Therapeutics Inc. (NEXL)

License/Use of six Diaclone monoclonal antibodies for ex vivo cell therapy, option for in vivo applications; applications include graft vs. host disease

Under amendment to 1/00 deal, Nexell has exclusive (rather than non-exclusive) license to the antibodies for ex vivo cell therapy

Genaissance Pharmaceuticals Inc. (GNSC)

Gene Logic Inc. (GLGC)

Database collaboration and subscription/Gene Logic will incorporate Genaissance's gene-specific genetic variation data into its GeneExpress database of gene expression information; Genaissance will subscribe to GeneExpress

ND

Genaissance Pharmaceuticals Inc. (GNSC)

Visible Genetics Inc. (VGIN)

License/Diagnostic and research applications of Genaissance's single-tube, single-step DNA sequencing technology covered by U.S. Patent No. 5,427,911

Companies amended 1996 agreement; Visible has rights to sublicense the technology, which is a component of its Trugene HIV-1 Genotyping Kit

Gene Logic Inc. (GLGC)

Psychiatric Genomics Inc.

Database subscription/Psychiatric Genomics acquired a license to a portion of Gene Logic's GeneExpress database system focusing on central nervous system samples

ND

Genentech Inc. (NYSE:DNA)

InterMune Pharmaceuticals Inc. (ITMN)

Marketing/Actimmune (interferon gamma-1b) injection for chronic granulomatous disease, osteoporosis, idiopathic pulmonary fibrosis and infectious diseases (FDA-approved and marketed by InterMune in the U.S.)

InterMune acquired rights to market Actimmune in Canada and will pay royalties to Genentech

Genzyme Molecular Oncology (GZMO)

Affymetrix Inc. (AFFX)

License/Use of Genzyme Molecular's rights to the p53 tumor-suppressor gene for use on Affymetrix's GeneChip arrays

Genzyme Molecular will receive an up-front payment, milestones and minimum royalties on the sale of future GeneChip products that utilize p53; GeneChip array customers will not have to seek an additional license from Genzyme Molecular

Genzyme Molecular Oncology (GZMO)

Medical Molecular Research Cologne (MEMOREC; Germany)

License/MEMOREC will make Genzyme's SAGE (serial analysis of gene expression) technology available to customers in Europe

ND

Geron Corp. (GERN)

Celera Genomics (NYSE:CRA)

Research collaboration/Discovery and analysis of genes important in early human development using Geron's pluripotent stem cell biology and Celera's sequencing and gene discovery expertise

Geron has rights to develop therapeutics and prenatal diagnostics; Celera will use data for genome annotation and to develop and commercialize probe sets for gene analysis

Hayashibara Biochemical Laboratories Inc.

Amarillo Biosciences Inc. (OTC BB:AMAR)

Development agreement/Expansion of agreement for natural human interferon gamma (under development in oral form) to include inhalation dosage

Amarillo now has worldwide rights (excluding Japan) to inhalable formulation, in addition to oral version

HeavenlyDoor.com (formerly Procept Inc.; HVDC)

Interneuron Pharmaceuticals Inc. (IPIC)

License/HeavenlyDoor's PRO 2000 Gel, a topical microbicide in clinical development

Interneuron gains exclusive worldwide rights in exchange for an up-front license fee, milestone payments and royalties; Interneuron will take over development activities

Ibis Therapeutics (division of Isis Pharmaceuticals; ISIP)

Agouron Pharmaceuticals Inc. (subsidiary of Pfizer Inc.; NYSE:PFE)

Research collaboration/Discovery and development of small-molecule RNA binders

Agouron will fund research, pay an up-front fee and make milestone payments totaling $37M for the first product

ID Biomedical Corp. (Canada; IDBE)

PE Biosystems Group (NYSE:PEB)

License/PE gains access to ID's intellectual property covering Cycling Probe Technology and will use the technology in genomics, high-throughput screening and dev